The hypothesis is that hCAP/LL-37 acts defensively against bacterial infections, including NTM disease, and that the population that originally had a low systemic secretory response to hCAP/LL-37 is more susceptible to NTM disease as a result. Here, CAMP is linked to bacterial infectious disease.